Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor

Fudan University

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT05797987

YOUNGBC-25

Details and patient eligibility

About

To investigate the treatment pattern and efficacy of patients with positive primary ER lesion but negative ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).

Enrollment: 52 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage.
• MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2010 and 2022
• Patients diagnosed with primary ER-positive tumor and who were yet to receive any systemic therapy during the advanced stage

Exclusion criteria

• Patients with incomplete medical records and those diagnosed with secondary primary tumors

Trial design

52 participants in 1 patient group

FES negative in MBC

Description:

Patients who did not present with any ER-positive lesions were characterized as with negative ER expression in the metastatic stage